Table 9 CSF findings in patients with monophasic disease and patients with relapsing disease. To control for differences in the number of follow-up samples available per patient, only the first LP performed during each acute event was considered

Pleocytosis, acute attacks

Samples

26/41 (63.4%)

19/40 (47.5%)^a

Pleocytosis, acute MY

Samples

14/16 (87.5%)

8/11 (72.7%)

Pleocytosis, acute ON

Samples

3/12 (25%)

2/13 (15.4%)

Pleocytosis, acute BRAIN

Samples

9/13 (69.2%)

9/16 (56.3%)

OCB, acute attacks

Samples

5/39 (12.8%)

4/40 (10%)^a

OCB, acute MY

Samples

4/17 (23.5%)

3/10 (30%)

OCB, acute ON

Samples

0/12 (0%)

0/14 (0%)

OCB, acute BRAIN

Samples

1/10 (10%)

1/16 (6.3%)

IgG-IF > 10%, acute attacks

Samples

3/36 (8.3%)

2/24 (8.3%)^a

IgG-IF > 10%, acute MY

Samples

2/16 (12.5%)

1/5 (20%)

IgG-IF > 10%, acute ON

Samples

0/12 (0%)

0/7 (0%)

IgG-IF > 10%, acute BRAIN

Samples

1/8 (12.5%)

1/12 (8.3%)

QAlb > Q_lim(Alb), acute attacks

Samples

18/36 (50%)

13/28 (46.4%)^a

QAlb > Q_lim(Alb), acute MY

Samples

11/16 (68.8%)

3/6 (50%)

QAlb > Q_lim(Alb), acute ON

Samples

3/12 (25%)

2/8 (25%)

QAlb > Q_lim(Alb), acute BRAIN

Samples

4/8 (50%)

8/14 (57.1%)

CSF TP elevated, acute attacks

Samples

10/39 (25.6%)

8/38 (21.1%)^a

CSF TP elevated, acute MY

samples

7/15 (46.7%)

3/10 (30%)

CSF TP elevated, acute ON

Samples

1/12 (8.3%)

0/12 (0%)

CSF TP elevated, acute BRAIN

Samples

2/12 (16.7%)

5/16 (31.3%)

CSF l-lactate elevated, acute attacks

Samples

14/33 (42.4%)

5/26 (19.2%)^a

CSF l-lactate elevated, acute MY

Samples

8/14 (57.1%)

2/6 (33.3%)

CSF l-lactate elevated, acute ON

Samples

2/10 (20%)

1/10 (10%)

CSF l-lactate elevated, acute BRAIN

Samples

4/9 (44.4%)

2/10 (20%)

Time since attack onset, acute LPs

Days

2 (0-33)

2 (0-40)